223 related articles for article (PubMed ID: 28765075)
1. Parkinson's disease-associated pathogenic VPS35 mutation causes complex I deficits.
Zhou L; Wang W; Hoppel C; Liu J; Zhu X
Biochim Biophys Acta Mol Basis Dis; 2017 Nov; 1863(11):2791-2795. PubMed ID: 28765075
[TBL] [Abstract][Full Text] [Related]
2. A conserved retromer sorting motif is essential for mitochondrial DLP1 recycling by VPS35 in Parkinson's disease model.
Wang W; Ma X; Zhou L; Liu J; Zhu X
Hum Mol Genet; 2017 Feb; 26(4):781-789. PubMed ID: 28040727
[TBL] [Abstract][Full Text] [Related]
3. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
[TBL] [Abstract][Full Text] [Related]
4. The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer.
Follett J; Norwood SJ; Hamilton NA; Mohan M; Kovtun O; Tay S; Zhe Y; Wood SA; Mellick GD; Silburn PA; Collins BM; Bugarcic A; Teasdale RD
Traffic; 2014 Feb; 15(2):230-44. PubMed ID: 24152121
[TBL] [Abstract][Full Text] [Related]
5. VPS35 and retromer dysfunction in Parkinson's disease.
Rowlands J; Moore DJ
Philos Trans R Soc Lond B Biol Sci; 2024 Apr; 379(1899):20220384. PubMed ID: 38368930
[TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes.
Wang W; Wang X; Fujioka H; Hoppel C; Whone AL; Caldwell MA; Cullen PJ; Liu J; Zhu X
Nat Med; 2016 Jan; 22(1):54-63. PubMed ID: 26618722
[TBL] [Abstract][Full Text] [Related]
7. VPS35, the Retromer Complex and Parkinson's Disease.
Williams ET; Chen X; Moore DJ
J Parkinsons Dis; 2017; 7(2):219-233. PubMed ID: 28222538
[TBL] [Abstract][Full Text] [Related]
8. (D620N) VPS35 causes the impairment of Wnt/β-catenin signaling cascade and mitochondrial dysfunction in a PARK17 knockin mouse model.
Chiu CC; Weng YH; Huang YZ; Chen RS; Liu YC; Yeh TH; Lu CS; Lin YW; Chen YJ; Hsu CC; Chiu CH; Wang YT; Chen WS; Liu SY; Wang HL
Cell Death Dis; 2020 Nov; 11(11):1018. PubMed ID: 33257649
[TBL] [Abstract][Full Text] [Related]
9. Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition.
Kadgien CA; Kamesh A; Milnerwood AJ
Mol Brain; 2021 Sep; 14(1):143. PubMed ID: 34530877
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease-linked
Chen X; Kordich JK; Williams ET; Levine N; Cole-Strauss A; Marshall L; Labrie V; Ma J; Lipton JW; Moore DJ
Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5765-5774. PubMed ID: 30842285
[TBL] [Abstract][Full Text] [Related]
11. Altered striatal dopamine levels in Parkinson's disease VPS35 D620N mutant transgenic aged mice.
Vanan S; Zeng X; Chia SY; Varnäs K; Jiang M; Zhang K; Saw WT; Padmanabhan P; Yu WP; Zhou ZD; Halldin C; Gulyás B; Tan EK; Zeng L
Mol Brain; 2020 Dec; 13(1):164. PubMed ID: 33261640
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.
Tsika E; Glauser L; Moser R; Fiser A; Daniel G; Sheerin UM; Lees A; Troncoso JC; Lewis PA; Bandopadhyay R; Schneider BL; Moore DJ
Hum Mol Genet; 2014 Sep; 23(17):4621-38. PubMed ID: 24740878
[TBL] [Abstract][Full Text] [Related]
13. VPS35 D620N knockin mice recapitulate cardinal features of Parkinson's disease.
Niu M; Zhao F; Bondelid K; Siedlak SL; Torres S; Fujioka H; Wang W; Liu J; Zhu X
Aging Cell; 2021 May; 20(5):e13347. PubMed ID: 33745227
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons.
Hanss Z; Larsen SB; Antony P; Mencke P; Massart F; Jarazo J; Schwamborn JC; Barbuti PA; Mellick GD; Krüger R
Mov Disord; 2021 Mar; 36(3):704-715. PubMed ID: 33142012
[TBL] [Abstract][Full Text] [Related]
15. VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin.
Malik BR; Godena VK; Whitworth AJ
Hum Mol Genet; 2015 Nov; 24(21):6106-17. PubMed ID: 26251041
[TBL] [Abstract][Full Text] [Related]
16. VPS35 mutation in Japanese patients with typical Parkinson's disease.
Ando M; Funayama M; Li Y; Kashihara K; Murakami Y; Ishizu N; Toyoda C; Noguchi K; Hashimoto T; Nakano N; Sasaki R; Kokubo Y; Kuzuhara S; Ogaki K; Yamashita C; Yoshino H; Hatano T; Tomiyama H; Hattori N
Mov Disord; 2012 Sep; 27(11):1413-7. PubMed ID: 22991136
[TBL] [Abstract][Full Text] [Related]
17. Contributions of VPS35 Mutations to Parkinson's Disease.
Rahman AA; Morrison BE
Neuroscience; 2019 Mar; 401():1-10. PubMed ID: 30660673
[TBL] [Abstract][Full Text] [Related]
18. The impact of VPS35 D620N mutation on alternative autophagy and its reversal by estrogen in Parkinson's disease.
Shiraishi T; Bono K; Hiraki H; Manome Y; Oka H; Iguchi Y; Okano HJ
Cell Mol Life Sci; 2024 Feb; 81(1):103. PubMed ID: 38409392
[TBL] [Abstract][Full Text] [Related]
19. D620N mutation in the VPS35 gene and R1205H mutation in the EIF4G1 gene are uncommon in the Greek population.
Kalinderi K; Bostantjopoulou S; Katsarou Z; Dimikiotou M; Fidani L
Neurosci Lett; 2015 Oct; 606():113-6. PubMed ID: 26300542
[TBL] [Abstract][Full Text] [Related]
20. Parkinson's Disease Causative Mutation in Vps35 Disturbs Tetherin Trafficking to Cell Surfaces and Facilitates Virus Spread.
Ding Y; Li Y; Chhetri G; Peng X; Wu J; Wang Z; Zhao B; Zhao W; Li X
Cells; 2021 Mar; 10(4):. PubMed ID: 33800686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
